Sample Record for Search: Drug Launches


Drug Name: piroxicam

Originator:

  • Pfizer (US) [Launched]
    Licensee:
  • Recalcine [Launched
  • Toyama Launched
  • Hermes Launched]

    Synonyms:

  • Algitrat NF
  • Baxo
  • Doblexan
  • Felden
  • Feldene
  • Ketazon
  • Prional
  • Proponol
  • Solocal m

    Chemical Name:
    2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2- pyridinyl-, 1,1-dioxide (CAS)
    CAS® Registry Number:

  • 36322-90-4

    Patent: 3,862,319 [US 3862319] United States of America
    Priority: February 9, 1971, United States of America (US)

    Text:
    Piroxicam is an anti-inflammatory agent, developed by Pfizer. It is equivalent in efficacy to indometacin in rheumatoid arthritis, with significant therapeutic effect in gout, ankylosing spondylitis and osteoarthritis. The maximum recommended dose is 20mg/day.

    Marketing

    It is launched as Feldene in Switzerland (79), Argentina, Austria, Central America, Chile, Greece, Ireland, S Korea, the UK, Nigeria, Hong Kong, Ecuador, Malaysia, Singapore (80), Finland, Pakistan, Germany, Belgium, Brazil, Canada, France, Italy, Mexico, the Netherlands, Peru, the Philippines, Portugal, S Africa, Spain, Thailand, Zimbabwe (81), Colombia, the US, Venezuela, Egypt, Indonesia (82), Australia and New Zealand and as Felden in Sweden (81), Denmark and Japan (82). It has also been launched as Algitrat NF (81) by Ricar as Prional by Exa; as Solocalm by Microsules and as Ketazon (82) by Elea in Argentina; as Proponol by Help in Greece (82); as Foldox by Recalcine in Chile (82); as Doblexan by Hermes in Spain (82) and as Baxo by Toyama in Japan (82) (Press release, Pfizer, Apr, 1982).

    Clinical

    Topical administration was effective in ocular inflammation (Opthalmology, 1982, 89, (98), 182). Updated by ML on 4/12/91.

    Status:

  • World Launched
  • Argentina Launched 80
  • Australia Launched
  • Austria Launched 80
  • Belgium Launched 81
  • Brazil Launched 81
  • Canada Launched 81
  • Colombia Launched 82
  • Denmark Launched 82
  • France Launched 81
  • Greece Launched 80
  • Ireland Launched 80
  • Italy Launched 81
  • Japan Launched 82
  • South Korea Launched 80
  • Mexico Launched 81
  • The Netherlands Launched 81
  • Peru Launched 81
  • The Philippines Launched 81
  • Portugal Launched 81
  • South Africa Launched 81
  • Spain Launched 81
  • Sweden Launched 81
  • Switzerland Launched 79
  • UK Launched 80
  • USA Launched 82
  • Venezuela Launched 82
  • Germany Launched 80

    Therapeutic Class:

  • Anti-inflammatory
  • Ophthalmological

    Pharmacological Code:

  • OX-C-AN, Enzyme, Oxidoreductase, Cyclooxygenase inhibitor, E-OR-OX-C-AN
  • SY-PG-AN, Enzyme, Oxidoreductase, Prostaglandin synthase inhibitor, Prostaglandin synthesis inhibitor, PG synthase inhibitor, E-OR-SY-PG-AN, 1.14.99.1

    Rating:
    Novelty:     E (Established therapy/mechanism combination)
    Development Speed: E (Development completed)
    Market Size: 5 (Therapeutic category market >$10001 million worldwide)
    Total Rating: N (Overall rating not available)

    Revision Date: October 17, 1997

    Pharmaprojects
    © 1997 PJB Publications, Ltd. All rights reserved.
    DIALOG® File Number 128 Accession Number 016713

    Top


     
    © 2012 Dialog LLC All Rights Reserved.